Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Crown Bioscience receives $26.55 million in Series D FundingInvestment to Fund Rapid Expansion in Translational Platform Technologies for Oncology and Metabolic Diseases
By: Crown Bioscience The investment, which closed on 25th April, will provide Crown with the ability to expand its technologies, including the HuPrime®, HuKemia®, HuBase™, HuMark™, HuTrial™ and HuSignature™ Dr Jean-Pierre Wery, President of Crown Bioscience, said; “The investment will allow us to expand our drug development services in oncology and metabolic disease to meet the demand and interest our technologies have generated through dramatically improving the clinical success of promising clinical candidates. Together with this, the investment will be used to actively pursue potential acquisition opportunities to further enhance our market leading position. Putting expansion plans into motion, we can offer partners the ability to test their drug candidates on a greater range of unique models, providing them with even better decision making potential before moving into clinical trials. Our patient-derived xenograph model (PDX) collection, HuPrime®, is now 1,000 models in size, and this funding will accelerate the pace at which we can expand the world’s largest collection of PDX.” Crown’s HuPrime PDX model collection is currently the largest collection of unique tumor xenograft models in the world, with the majority kept in live passage in order to run HuTrialTM, human surrogate clinical trial simulations. By expanding the HuPrime collection further, the HuTrial platform will be able to more accurately predict the efficacy of potential drug candidates on a greater number of varied cancer subtypes before advancing the candidate into the clinic. This will significantly reduce development costs and ensure that the most effective treatments progress through trials and go on to improving patient outcomes in the clinic. ### About Crown Bioscience Inc. Founded in 2006, Crown Bioscience is a premier drug discovery and development service company providing cutting-edge translational platforms and cost effective drug discovery solutions for its biotech and pharmaceutical partners in dedicated therapeutic areas: Oncology and Metabolic Disease. Our proprietary HuPrime®, HuKemia®, HuBase™, HuMark™, HuTrial™ and HuSignature™ For further press information please contact: David Bertram - The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire, CW4 8AA, United Kingdom. Tel: + 44 1477 539 539 Fax: +44 1477 539 540 E-mail: crown@scottpr.com End
|
|